Emerging data suggests that Cilgavimab, formerly known as COV2-2130, demonstrates significant potential as a therapeutic agent against the coronavirus . This protein exhibits a novel method of operation , particularly neutralizing the viral ACE2 interface with considerable binding power. Early trials show a significant power to prevent viral entry